LabConnect Partners with Kits4Life to Reduce Waste and Promote Sustainable Clinical Trials

LabConnect and Kits4Life: A Sustainable Partnership for Clinical Research

In a significant initiative to reduce waste in clinical trials, LabConnect has unveiled its partnership with Kits4Life, a MedSurplus Alliance initiative. This collaboration aims to address the environmental challenges associated with clinical studies by implementing sustainable practices and promoting global health equity.

Clinical trials are crucial for developing new therapies that can change lives; however, they often lead to substantial material waste, prominently in the form of unused and expired collection kits. These kits usually consist of high-quality medical supplies that could be reused when donated to underserved communities facing dire medical needs. Julia Tarasenko, Chief Commercial and Strategy Officer at LabConnect, stated, “We are excited to work with Kits4Life to reclaim surplus kits from clinical trials and ensure they are ethically and safely donated to organizations in need.”

LabConnect’s commitment to environmental, social, and governance (ESG) strategies demonstrates its leadership in sustainable clinical research. By identifying excess kits for donation and managing their distribution, LabConnect not only aims to minimize procurement waste but also seeks to improve access to vital health resources where they are needed most.

The partnership is part of LabConnect’s broader ESG strategy, which encompasses lowering carbon emissions, ensuring ethical sourcing, and fostering civic engagement throughout the clinical research lifecycle. “We believe that sustainability and scientific innovation do not have to be mutually exclusive but can instead enhance each other. As clinical research evolves, partnerships like this help pave the way toward a future where environmental responsibility and groundbreaking therapies go hand in hand,” Tarasenko added.

LabConnect is well known as a premier provider of central lab services, focusing on analytical and logistical complexities of trials in areas such as immuno-oncology, cell and gene therapies, and rare diseases. Its unique combination of advanced technology, top-tier laboratories, and extensive expertise in specialty tests makes LabConnect a preferred partner for pharmaceutical development companies seeking central lab services.

In conclusion, the collaboration between LabConnect and Kits4Life marks a substantial step towards creating a more responsible and sustainable approach to clinical trials. By transforming excess materials into critical resources for those in need, this partnership not only addresses waste reduction but also embodies a dedication to social equity in healthcare.

For more information about LabConnect and its services, visit www.labconnect.com. Follow them on LinkedIn for updates on their ongoing initiatives.